Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.6950
-0.0030 (-0.43%)
At close: Jan 8, 2026, 4:00 PM EST
0.6701
-0.0249 (-3.58%)
After-hours: Jan 8, 2026, 7:28 PM EST
Lexaria Bioscience Revenue
In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth. Lexaria Bioscience had revenue of $174.00K in the quarter ending August 31, 2025, with 107.14% growth.
Revenue (ttm)
$705.92K
Revenue Growth
+52.05%
P/S Ratio
17.72
Revenue / Employee
$100,846
Employees
7
Market Cap
17.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LEXX News
- 9 days ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire
- 16 days ago - Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
- 16 days ago - Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Accesswire
- 23 days ago - Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 24 days ago - Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Accesswire
- 3 months ago - Lexaria Bioscience Corp. Provides Strategic Update - Accesswire
- 3 months ago - Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire